Trial · NCT00723801
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
NCT00723801, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2014-09-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome. Trials, record NCT00723801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00723801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
- NCT number
- NCT00723801
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Marfan Syndrome
- Interventions
- Atenolol, Losartan
- First posted
- 2008-07-29
- Last updated
- 2014-09-09
- Results first posted
- 2014-09-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Aortic Biophysical Properties - Pulse Wave Velocity | Baseline and 6 months | Aortic stiffness was assessed using applanation tonometry (SphygmoCor®, AtCor Medical, West Ryde, NSW, Sydney, Australia) to measure carotid to femoral artery pulse wave velocity (PWV). With the patient lying supine in a quiet environment, a handheld micromanometer-tipped probe was applied to the skin surface over the carotid and femoral arteries, compressing the vessel wall so that transmural forces within the vessel wall were perpendicular to the arterial surface. The distance from the sternal notch to the sites of carotid and femoral pulse acquisition were measured and inputted into the device to represent the relative distance from the carotid to femoral artery. The calculation of distance divided by time of pulse upstroke relative to the upstroke of the QRS on a 3 lead surface EKG was used by the device to calculate velocity. All recorded measurements met the manufacturer's quality control standards integrated into the software package. |
| Secondary | Diastolic Function - Ejection Fraction | Baseline and 6 months | Two-dimensional echocardiography was performed using a 3.0 MHz transducer (General Electric VIVID 7). Left ventricular and left atrial dimensions were determined in parasternal long axis views. Left ventricular ejection fraction was calculated using the modified Simpsons calculation in the apical two and four chamber views. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Aortic Biophysical Properties - Pulse Wave Velocity | Baseline and 6 months | change in meters/second | MEAN | |
| SECONDARY | Diastolic Function - Ejection Fraction | Baseline and 6 months | Change in % ejection fraction | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Aortic Biophysical Properties - Pulse Wave Velocity | Subjects Randomized to Atenolol | -1.15 | Standard Deviation 1.68 | change in meters/second | |
| Aortic Biophysical Properties - Pulse Wave Velocity | Subjects Randomized to Losartan | -0.22 | Standard Deviation .59 | change in meters/second | |
| Diastolic Function - Ejection Fraction | Subjects Randomized to Atenolol | 1.31 | Standard Deviation 4.07 | Change in % ejection fraction | |
| Diastolic Function - Ejection Fraction | Subjects Randomized to Losartan | 1.57 | Standard Deviation 8.29 | Change in % ejection fraction |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Subjects Randomized to Atenolol | 20 | |
| Overall Study | STARTED | Subjects Randomized to Losartan | 20 | |
| Overall Study | COMPLETED | Subjects Randomized to Atenolol | 17 | |
| Overall Study | COMPLETED | Subjects Randomized to Losartan | 17 | |
| Overall Study | NOT COMPLETED | Subjects Randomized to Atenolol | 3 | |
| Overall Study | NOT COMPLETED | Subjects Randomized to Losartan | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Subjects Randomized to Atenolol | ||
| Total, all-cause mortality | Subjects Randomized to Losartan | ||
| Total, other adverse events | Subjects Randomized to Atenolol | 0 | 20 |
| Total, other adverse events | Subjects Randomized to Losartan | 0 | 20 |
| Total, serious adverse events | Subjects Randomized to Atenolol | 0 | 20 |
| Total, serious adverse events | Subjects Randomized to Losartan | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Subjects Randomized to Atenolol vs Subjects Randomized to Losartan: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00723801
GET https://conductscience.org/api/trials/v1/NCT00723801/registered